MiGenTra GmbH is a biotech company developing new biological therapies and gene therapies to ensure affordable access to essential medicines in Egypt, the Middle East, and Africa. The company currently has six biologics and two gene therapies in its pipeline. It’s also in advanced talks with financial institutions to raise $100 million. The company’s initial investments were obtained from Minapharm Pharmaceuticals, an Egyptian-based biopharmaceutical, of which Bardissi is a co-CEO. The company expects its first biologic therapy to enter the market in 2023, while gene therapy will be available in 2027.